Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ANGO Stock Forecast 2026-2027
$10.46
Current Price
$432.20M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ANGO Price Targets
+129.4%
To High Target of $24.00
+53.0%
To Median Target of $16.00
+53.0%
To Low Target of $16.00
ANGO Price Momentum
+6.7%
1 Week Change
+0.6%
1 Month Change
+9.9%
1 Year Change
-18.5%
Year-to-Date Change
-25.2%
From 52W High of $13.99
+25.1%
From 52W Low of $8.36
📊 TOP ANALYST CALLS
Did ANGO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if AngioDynamics is one of their latest high-conviction picks.
Latest ANGO Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, ANGO has a bullish consensus with a median price target of $16.00 (ranging from $16.00 to $24.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $10.46, the median forecast implies a 53.0% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Frank Takkinen at Lake Street, projecting a 129.4% upside. Conversely, the most conservative target is provided by Ilya Zubkov at Freedom Broker, suggesting a 53.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ANGO Analyst Ratings
4
Buy
0
Hold
0
Sell
ANGO Price Target Range
Low
$16.00
Average
$16.00
High
$24.00
Current: $10.46
Latest ANGO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ANGO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 6, 2026 | Freedom Broker | Ilya Zubkov | Buy | Initiates | $16.00 |
| Apr 6, 2026 | Canaccord Genuity | John Young | Buy | Maintains | $16.00 |
| Oct 3, 2025 | Canaccord Genuity | William Plovanic | Buy | Maintains | $18.00 |
| Jul 16, 2025 | Lake Street | Frank Takkinen | Buy | Initiates | $24.00 |
| Jul 16, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $16.00 |
| Jul 16, 2025 | Canaccord Genuity | William Plovanic | Buy | Maintains | $17.00 |
| Apr 7, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $16.00 |
| Jan 10, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $15.00 |
| Jan 9, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Dec 10, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $14.00 |
| Oct 4, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $14.00 |
| Oct 4, 2024 | Canaccord Genuity | William Plovanic | Buy | Maintains | $12.00 |
| Sep 20, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $14.00 |
| Jul 17, 2024 | Canaccord Genuity | William Plovanic | Buy | Maintains | $13.00 |
| Jul 17, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $14.00 |
| May 22, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $14.00 |
| Apr 5, 2024 | Oppenheimer | Steven Lichtman | Outperform | Upgrade | $12.00 |
| Jan 9, 2024 | Raymond James | Jayson Bedford | Outperform | Maintains | $10.00 |
| Jan 8, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $18.00 |
| Oct 6, 2023 | Raymond James | Jayson Bedford | Outperform | Maintains | $12.00 |
Angiodynamics Inc. (ANGO) Competitors
The following stocks are similar to AngioDynamics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ANGO
AngioDynamics
mkt cap
404.93M
Angiodynamics Inc. (ANGO) Financial Data
Angiodynamics Inc. has a market capitalization of $432.20M with a P/E ratio of 41.4x. The company generates $313.72M in trailing twelve-month revenue with a -10.0% profit margin.
Revenue growth is +8.9% quarter-over-quarter, while maintaining an operating margin of -8.2% and return on equity of -17.5%.
Valuation Metrics
Market Cap
$432.20M
Enterprise Value
$409.58M
P/E Ratio
41.4x
PEG Ratio
0.6x
Price/Sales
1.4x
Growth & Margins
Revenue Growth (YoY)
+8.9%
Gross Margin
+52.9%
Operating Margin
-8.2%
Net Margin
-10.0%
EPS Growth
+8.9%
Financial Health
Cash/Price Ratio
+8.7%
Current Ratio
2.4x
Debt/Equity
6.6x
ROE
-17.5%
ROA
-4.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Angiodynamics Inc. (ANGO) Business Model
About Angiodynamics Inc.
What They Do
Develops medical devices for vascular and oncology treatments.
Business Model
The company generates revenue by designing, manufacturing, and selling a diverse range of medical devices aimed at treating peripheral vascular disease and oncology. AngioDynamics operates through its Med Tech and Med Device segments, providing innovative and minimally invasive solutions that cater to the needs of healthcare professionals and improve patient outcomes.
Additional Information
Founded in 1988 and headquartered in Latham, New York, AngioDynamics has a global presence with facilities in North America, Europe, APAC, the Middle East, and South America. Its key products include the Auryon Atherectomy system and AlphaVac mechanical thrombectomy system, among others, contributing to its reputation as a significant player in the medical devices sector.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
675
CEO
Mr. James C. Clemmer
Country
United States
IPO Year
2004
Website
www.angiodynamics.comAngiodynamics Inc. (ANGO) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
AngioDynamics (ANGO) Upgraded to Buy: Here's Why
AngioDynamics (ANGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Apr 08, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
AngioDynamics (ANGO) Loses 5.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
7 days ago
Quick Summary
AngioDynamics (ANGO) is currently in oversold territory, and Wall Street analysts are revising earnings estimates higher, suggesting a potential trend reversal.
Why It Matters
AngioDynamics may be poised for a rebound as it's in oversold territory, coupled with analysts revising earnings estimates upward, suggesting potential price appreciation.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
AngioDynamics (ANGO) has been upgraded to a Zacks Rank #2 (Buy), indicating increased optimism regarding its earnings prospects.
Why It Matters
AngioDynamics' upgrade to a Zacks Rank #2 signals increased earnings potential, likely boosting investor confidence and driving stock price growth.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
AngioDynamics reports higher revenue and reduced losses, exceeding estimates, fueled by demand in the Med Tech sector, though gross margin has declined.
Why It Matters
AngioDynamics' revenue growth and reduced losses indicate strong demand in Med Tech, signaling potential for future profitability, despite a slight decline in gross margin.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
AngioDynamics shows strong growth in its Med Tech sector, with AlphaVac up 47% and NanoKnife up 21%. However, Q4 guidance is mixed due to rising costs, despite increased revenue forecasts.
Why It Matters
AngioDynamics shows growth potential with strong product performance, but ongoing costs and margin pressures create volatility, affecting short-term investor sentiment and valuation.
Source: Seeking Alpha
Market Sentiment:
Negative
Quick Summary
AngioDynamics, Inc. reported its Q3 2026 earnings, providing insights into financial performance and outlook. For detailed figures and analysis, refer to the full earnings call transcript.
Why It Matters
AngioDynamics' Q3 2026 earnings reveal financial performance, impacting stock valuation, investor sentiment, and future growth projections. Key metrics can indicate operational health and market position.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
AngioDynamics, Inc. reported third-quarter fiscal 2026 net sales of $78 million, reflecting year-over-year growth, as it focuses on vascular health and cancer treatment solutions.
Why It Matters
AngioDynamics' financial performance indicates growth in net sales, highlighting its market position and potential for future profitability, which impacts investor confidence and stock valuation.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About ANGO Stock
What is Angiodynamics Inc.'s (ANGO) stock forecast for 2026?
Based on our analysis of 10 Wall Street analysts, Angiodynamics Inc. (ANGO) has a median price target of $16.00. The highest price target is $24.00 and the lowest is $16.00.
Is ANGO stock a good investment in 2026?
According to current analyst ratings, ANGO has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $10.46. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ANGO stock?
Wall Street analysts predict ANGO stock could reach $16.00 in the next 12 months. This represents a 53.0% increase from the current price of $10.46. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Angiodynamics Inc.'s business model?
The company generates revenue by designing, manufacturing, and selling a diverse range of medical devices aimed at treating peripheral vascular disease and oncology. AngioDynamics operates through its Med Tech and Med Device segments, providing innovative and minimally invasive solutions that cater to the needs of healthcare professionals and improve patient outcomes.
What is the highest forecasted price for ANGO Angiodynamics Inc.?
The highest price target for ANGO is $24.00 from Frank Takkinen at Lake Street, which represents a 129.4% increase from the current price of $10.46.
What is the lowest forecasted price for ANGO Angiodynamics Inc.?
The lowest price target for ANGO is $16.00 from Ilya Zubkov at Freedom Broker, which represents a 53.0% increase from the current price of $10.46.
What is the overall ANGO consensus from analysts for Angiodynamics Inc.?
The overall analyst consensus for ANGO is bullish. Out of 10 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $16.00.
How accurate are ANGO stock price projections?
Stock price projections, including those for Angiodynamics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 17, 2026 3:19 PM UTC